Form 4: Equillium COO Sells Shares After Option Exercise

Equillium's Sr. Vice President and COO, Christine Zedelmayer, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Christine Zedelmayer, Sr. Vice President and COO of Equillium, Inc. (EQ), reported transactions on February 19, 2026.
• Exercised 109,375 employee stock options at an exercise price of $0.785 per share.
• Sold 109,375 shares of common stock at an average price of $1.7814 per share.
• Exercised an additional 76,562 employee stock options at an exercise price of $0.73 per share.
• Sold 76,562 shares of common stock at an average price of $1.7406 per share.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 27, 2025.
• Following these transactions, Christine Zedelmayer beneficially owns 191,444 shares of common stock directly.
• Remaining derivative securities include 15,625 employee stock options with an exercise price of $0.785 and 98,438 employee stock options with an exercise price of $0.73.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine insider transaction for equity compensation management under a pre-arranged plan, rather than a discretionary sale based on new information.

Positives

• The executive exercised in-the-money stock options, indicating a profit on the exercise.

Negatives

• A significant number of shares were sold by a senior executive, though this was pre-planned.

Future Outlook

NA

Management Comments

• The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2025.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, are routine for executives managing their equity compensation and do not inherently signal a change in company fundamentals or broader industry trends.

Stakeholder Impact

• Shareholders: The sale by a senior executive, while under a 10b5-1 plan, is a routine event for equity compensation realization and is generally not considered a significant indicator of future company performance.

Next Steps

• Remaining employee stock options will continue to vest according to their schedule (25% on first anniversary, then 36 equal monthly installments).

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-established 10b5-1 trading plan. Such transactions are common for executives managing their equity compensation and typically do not reflect new material information about the company's prospects. Therefore, it provides no new fundamental basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Equillium, EQ, insider trading, Form 4, stock options, executive compensation, Christine Zedelmayer, 10b5-1 plan